Back to School: How biopharma can reboot drug development. Access exclusive analysis here
In a double-blind Phase II study of 58 patients with UTI, Ciprofloxacin GR was
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury